Monitor upcoming regulatory decisions and commercial updates for miv-cel, as this appointment signals preparation for a potential launch. No immediate stock-moving catalyst.
Price Chart
Executive Summary
Kyverna Therapeutics appointed Nadia Dac as Chief Commercial Officer, effective May 4, 2026. She brings over 30 years of commercial leadership in neurology and rare disease, and will lead launch preparations for miv-cel in stiff person syndrome. The appointment is routine and does not change the company's financial outlook.
Key Facts
- Nadia Dac appointed Chief Commercial Officer effective May 4, 2026
- Ms. Dac has 30+ years of commercial experience including launches at Omeros, Alder, AbbVie
- Inducement stock option grant of 300,000 shares, vesting over 4 years
- She will lead commercial strategy for miv-cel (KYV-101) in stiff person syndrome
Financial Impact
No financial impact disclosed; option grant is standard inducement
Risk Factors
- Execution risk in transitioning to commercial stage
- Regulatory approval uncertainty for miv-cel
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-202610 |
| Document: kytx-ex99_1.htm | 0001193125-26-202610 |
| Document: 0001193125-26-202610-index-headers.html | 0001193125-26-202610 |
| Document: 0001193125-26-202610-index.html | 0001193125-26-202610 |
| Document: 0001193125-26-202610.txt | 0001193125-26-202610 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.27 (−9.61%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.27 (−24.61%) |
Aug 11, 2026 10w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Aug 11, 2026 10w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.27 (−33.46%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.27 (−46.28%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.27 (+34.57%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.27 (−41.44%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.27 (−48.48%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.27 (−53.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers